Moreover, treatment with another PPARγ agonist, pioglitazone, attenuates the production of Aβ plaque burden and glial inflammation in the APPV717I transgenic mice [83] and cognitive impairments in AD patients [92]. This evidence concerns the gene PPARG and Cognitive impairment.